These patients were resistant to anti-PD-1/PD-L1 immunotherapy, the reason may be that angiogenesis leads to the activation of tumor glycolysis, resulting in an immunosuppressive tumor microenvironment. This evidence concerns the gene PDCD1 and neoplasm.